Lukas Polakovic

perfect match, roche + Sysmex example of a TLA, with a goal to serve 30 million patients over the next decade, this partnership shows what’s possible when purpose-driven organizations join forces for the greater good. https://lnkd.in/exRjaeYy

37

1 Kommentar

#SAN.PA: Sanofi is transforming into a focused biopharma powerhouse, prioritizing long-term innovation over short-term margins. Dupixent’s sustained double-digit growth and a robust late-stage pipeline show strong future promise. Shares trade at a steep discount to peers despite resilient financials. Could Sanofi’s coming strategic moves unlock significant value for investors?

𝗟𝗮𝘁𝗲𝘀𝘁 𝗚𝗲𝗻𝗲𝗿𝗶𝗰𝘀 𝗮𝗻𝗱 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗡𝗲𝘄𝘀 Your weekly round-up of what’s happening across the world of generics and biosimilars. Parsity Pulse – Volume 47. We provide a clear snapshot of the latest industry news each week, covering major M&A, regulatory shifts, market trends, and innovation updates. 𝗚𝗲𝗻𝗲𝗿𝗶𝗰𝘀 𝗻𝗲𝘄𝘀 🔹 STADA Group reports record growth, with 2025 revenues reaching €4.3bn. Its generics segment continues to outperform, with top-three retail rankings across Germany, Italy, and Spain. 🔹 Lupin and Zydus Group partner on semaglutide, signing a licensing deal to co-market a generic injection in India under the Livarise brand, using a reusable pen device. 🔹 Lupin Pharmaceuticals expands peptide manufacturing at its Dabhasa facility to support rising global demand for complex generics, including GLP-1 agonists. 🔹 Teva Pharmaceuticals confirms its Pivot to Growth strategy is on track, focusing on high-margin complex generics and its growing immunology pipeline, including duvakitug. 🔹 NHS England outlines a five-year strategy for high-value generics, focusing on system readiness for medicines coming on tariff this year. 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗻𝗲𝘄𝘀 🔹 Sandoz and Samsung Bioepis partner to develop and commercialise up to five next-generation biosimilars, starting with an Entyvio-referencing asset. 🔹 Formycon AG and Samsung Bioepis settle Eylea disputes. Formycon and its partner reached a settlement with Regeneron and Bayer. The agreement resolves all patent litigation in Europe for its aflibercept biosimilar, clearing the path for a 2026 market entry. 🔹 Henlius reports sustained profitability in 2025, driven by trastuzumab biosimilar sales, and gains FDA clearance for US trials of its nivolumab biosimilar. 🔹 Samsung Bioepis and G2GBIO collaborate to develop long-acting therapeutics, including semaglutide, targeting obesity and diabetes markets. 🔹 Sandoz creates a dedicated biosimilars unit to streamline development and accelerate its 32-asset pipeline. At Parsity Group, we specialise in building agile executive leadership teams for pharma and life sciences. If you're looking for expert advice, market insight, or support with your next executive hire, we’re your go-to partner. 📲 𝗙𝗼𝗹𝗹𝗼𝘄 𝘂𝘀 𝗳𝗼𝗿 𝗺𝗼𝗿𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀. #generics #biosimilars #pharma #news

12

2 Kommentare

Haleon has appointed Maimai Madrid - Punzalan as its new general manager for the Philippines, marking a major leadership move for the consumer healthcare giant behind Centrum, Sensodyne, Robitussin, and more. She steps into the role as former PH GM Jeffrey Go takes on Haleon Taiwan. With over 20 years of experience across FMCG and the startup ecosystem, Punzalan joins as Haleon accelerates its "Win as One" strategy to reach one billion more consumers by 2030. Data shows 6 in 10 Filipinos now take multivitamins, reflecting rising demand for preventive health. "Haleon's purpose to deliver better everyday health with humanity resonates strongly with me," said Punzalan. "It's a privilege to lead a company that deeply understands the lives of Filipinos and is dedicated to caring for their overall health and well-being." Read the full story here: https://lnkd.in/gXydNvBh Follow our Telegram channel for the latest updates: https://lnkd.in/g5bVK85

6

Access to quality diabetes care shouldn't depend on where you live. In India, millions face barriers to consistent diabetes management. That's why our 30+ year collaboration with Abbott has evolved into something bigger—a strengthened partnership focused on expanding access to diabetes care across the country. What makes partnerships like this work? 🔹 Shared commitment to patients 🔹 Decades of trust, tested and earned 🔹 The capability to scale solutions responsibly Real progress happens when organisations align on purpose. Together with Abbott, we're working to ensure more people living with diabetes can access the care they need. Vikrant Shrotriya Kartik Rajendran

813

8 Kommentare

Today marks an important milestone for Galderma and Sandoz as both companies have joined the Swiss Market Index (SMI), Switzerland's leading blue-chip index, as the index adjustments come into effect following the ordinary index review. Since their respective listings on SIX Swiss Exchange in 2023 and 2024, both companies have demonstrated strong market relevance and growth, earning their place among Switzerland's most prominent listed companies. We congratulate Galderma and Sandoz and wish them continued success in the Swiss capital market. Learn more about our Swiss Stock Indices: https://six.swiss/4jbuhuP #SMI #SwissMarketIndex #MakingADifferenceWithData SIX Swiss Exchange SIX

26

A powerhouse of science, innovation, and real-world impact. The Grand Dermatology Symposium in New Delhi brought together India's leading dermatologists and key opinion leaders for an exclusive exchange of scientific knowledge. At the heart of it all, Professor Dr. Gabriel Serrano, Founder & President of Sesderma Group, sharing insights from over 35 years of pioneering work in dermatology. He led three exclusive sessions: * Skin & Body Regeneration * Next Generation Micro-Needling * High Phototype Peels And honestly? The conversations are still echoing, the questions are still buzzing, and we're still processing all the brilliance that unfolded. #GrandDermatologySymposium #DermatologySymposium #DermatologyConference #MedicalConference #DermatologyIndia #AestheticDermatology #SkinScience #MedicalEducation #Iberia #GabrielSerrano

3

‘We’re Not Done’: Roche Plans to Sustain Dealmaking Pace After 89bio Roche still has some deals to do after two high profile agreements in recent weeks: “We’re not done with BD,” CEO Thomas Schinecker said during a third quarter earnings call this week. Schinecker did not specify which potential partners Roche has its eye on or what particular spaces it wants to deal in. “We can continue to invest in [business development] and bring in more opportunities that will continue to drive growth,” he said. As is usual for the company, its pharmaceuticals business represented the bulk of its earnings, surging 9% to $44.54 billion. Diagnostics made $12.92 billion from January to September, a 1% increase versus the same period in 2024. https://lnkd.in/gWJVU3t5 #aspenalert #biotech #bioprocess

1